StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

ArriVent BioPharma total assets

Total assets on the balance sheet at the end of each period.

ArriVent BioPharma's total assets was $394.72M at Jun 30, 2026. For fiscal 2025 it was $333.17M, up 21.2% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$333.17M+21.2%
FY2024Dec 31, 2024$274.94M+68.6%
FY2023Dec 31, 2023$163.10M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$394.72M+46.5%
Q1 FY2026Mar 31, 2026$349.30M+62.1%
Q4 FY2025Dec 31, 2025$333.17M+21.2%
Q3 FY2025Sep 30, 2025$326.56M+11.6%
Q2 FY2025Jun 30, 2025$269.51M-12.7%
Q1 FY2025Mar 31, 2025$215.50M-34.3%
Q4 FY2024Dec 31, 2024$274.94M+68.6%
Q3 FY2024Sep 30, 2024$292.71M–
Q2 FY2024Jun 30, 2024$308.86M–
Q1 FY2024Mar 31, 2024$327.84M–
Q4 FY2023Dec 31, 2023$163.10M–

More ArriVent BioPharma figures

See a number that looks wrong?